U-62066 - Moligand™ , Agonist of κ receptor, CAS No.87151-85-7, Agonist of κ receptor

CAS: 87151-85-7 Cat. No.: U333272 Formula: C22H30Cl2N2O2·CH3SO3H Peso molecolare: 521.5
Disponibile su ordine
QUALITÀ & PUREZZA Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools.
Synonyms
2-(3,4-dichlorophenyl)-N-methyl-N-[(5R,7S,8S)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide|2-(3,4-dichlorophenyl)-N-methyl-N-[(5R,7S,8S)-7-pyrrolidino-1-oxaspiro[4.5]decan-8-yl]acetamide;mesylic acid|Benzeneacetamide, 3,4-dichloro-N-methyl-N-(7-(1-pyrrolidinyl)-1-oxaspiro(4,5)dec-8-yl)-, (5alpha,7alpha,8beta)-(+-)-|Spiradoline [INN]|2-(3,4-dichlorophenyl)-N-methyl-N-[(5R,7S,8S)-7-(1-pyrrolidinyl)-1-oxaspiro[4.5]decan-8-yl]acetamide;methanesulfonic acid|Spiradolinum [Latin]|2-(3,4-dichlorophenyl)-N-methyl-N-[(5R,7S,8S)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]ethanamide;methanesulfonic acid|U62066|Espiradolina|Spiradolinum|Espiradolina [Spanish]|SPIRADOLINE
Storage
Store at 2-8°C
Shipped In
Wet ice
★
Dimensione
Germania (EU)
USA*
Prezzo
Qtà
25mg
U333272-25mg
Su ordinazione · 8–12 settimane
121,40€
Enter a quantity for the sizes you want to add.

Panoramica

U-62066 is a highly selective κ opioid receptor agonist as well as an antitussive.

Specifiche

Sinonimi
2-(3,4-dichlorophenyl)-N-methyl-N-[(5R,7S,8S)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide | 2-(3,4-dichlorophenyl)-N-methyl-N-[(5R,7S,8S)-7-pyrrolidino-1-oxaspiro[4.5]decan-8-yl]acetamide;mesylic acid | Benzeneacetamide, 3,4-dichloro-N-methyl-N-(7-(1-pyrrolidinyl)-1-oxaspiro(4,5)dec-8-yl)-, (5alpha,7alpha,8beta)-(+-)- | Spiradol Mostra altro
Specifiche e purezza
Moligand™
Condizioni di conservazione di stoccaggio
Store at 2-8°C
Spedito in
Wet ice
Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.
Grado
Moligand™
Tipo di azione
AGONIST
Meccanismo d'azione
Agonist of κ receptor
Nomi e identificatori
SMILES
CN(C1CCC2(CCCO2)CC1N3CCCC3)C(=O)CC4=CC(=C(C=C4)Cl)Cl
IUPAC Name
2-(3,4-dichlorophenyl)-N-methyl-N-[(5R,7S,8S)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]acetamide
InChIKey
NYKCGQQJNVPOLU-ONTIZHBOSA-N
InChI
1S/C22H30Cl2N2O2/c1-25(21(27)14-16-5-6-17(23)18(24)13-16)19-7-9-22(8-4-12-28-22)15-20(19)26-10-2-3-11-26/h5-6,13,19-20H,2-4,7-12,14-15H2,1H3/t19-,20-,22-/m0/s1
Isomeri SMILES
CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N3CCCC3)C(=O)CC4=CC(=C(C=C4)Cl)Cl
WGK Germania
3
Peso molecolare
521.5
Reaxy-Rn
8169904
Reaxys-RN_link_address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=8169904&ln=

Dati avanzati

Taxonomic Classification

Taxonomy Tree

KingdomOrganic compounds
SuperclassBenzenoids
ClasseBenzene and substituted derivatives
SubclassPhenylacetamides
Intermediate Tree Nodes Not available
Direct ParentPhenylacetamides
Alternative Parents Dichlorobenzenes  N-alkylpyrrolidines  Aryl chlorides  Tetrahydrofurans  Tertiary carboxylic acid amides  Trialkylamines  Amino acids and derivatives  Oxacyclic compounds  Dialkyl ethers  Azacyclic compounds  Organopnictogen compounds  Organochlorides  Organic oxides  Hydrocarbon derivatives  Carbonyl compounds  
Molecular FrameworkAromatic heteropolycyclic compounds
Substituents Phenylacetamide - 1,2-dichlorobenzene - Chlorobenzene - Halobenzene - Aryl chloride - Aryl halide - N-alkylpyrrolidine - Pyrrolidine - Tetrahydrofuran - Tertiary carboxylic acid amide - Amino acid or derivatives - Carboxamide group - Tertiary aliphatic amine - Tertiary amine - Carboxylic acid derivative - Dialkyl ether - Oxacycle - Ether - Azacycle - Organoheterocyclic compound - Organic oxygen compound - Organic nitrogen compound - Hydrocarbon derivative - Amine - Organic oxide - Organopnictogen compound - Organohalogen compound - Organochloride - Organonitrogen compound - Organooxygen compound - Carbonyl group - Aromatic heteropolycyclic compound
DescrizioneThis compound belongs to the class of organic compounds known as phenylacetamides. These are amide derivatives of phenylacetic acids.
External Descriptors Not available
Struttura 3D
Modello di struttura chimica interattiva





Obiettivi associati (umani)
OPRK1 Tclin Kappa-type opioid receptor (5 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
OPRM1 Tclin Mu-type opioid receptor (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
PDE5A Tclin Phosphodiesterase 5A (5113 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
EGFR Tclin Epidermal growth factor receptor erbB1 (33727 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CA2 Tclin Carbonic anhydrase II (17698 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ESR1 Tclin Estrogen receptor alpha (17718 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HMGCR Tclin HMG-CoA reductase (2475 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NR3C1 Tclin Glucocorticoid receptor (14987 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
INSR Tclin Insulin receptor (5558 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PGR Tclin Progesterone receptor (8562 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRB2 Tclin Beta-2 adrenergic receptor (11824 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHRM2 Tclin Muscarinic acetylcholine receptor M2 (10671 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRB1 Tclin Beta-1 adrenergic receptor (6630 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR1A Tclin Serotonin 1a (5-HT1a) receptor (14969 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA2A Tclin Alpha-2a adrenergic receptor (9450 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AR Tclin Androgen Receptor (11781 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHRM1 Tclin Muscarinic acetylcholine receptor M1 (12690 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ACE Tclin Angiotensin-converting enzyme (1423 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DRD2 Tclin Dopamine D2 receptor (23596 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MAOA Tclin Monoamine oxidase A (11911 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CNR1 Tclin Cannabinoid CB1 receptor (20913 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DRD1 Tclin Dopamine D1 receptor (9720 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DRD4 Tchem Dopamine D4 receptor (7907 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ACHE Tclin Acetylcholinesterase (18204 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PTGS1 Tclin Cyclooxygenase-1 (9233 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC6A2 Tclin Norepinephrine transporter (10102 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HRH2 Tclin Histamine H2 receptor (5428 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA1D Tclin Alpha-1d adrenergic receptor (4171 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR1B Tclin Serotonin 1b (5-HT1b) receptor (2801 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR2A Tclin Serotonin 2a (5-HT2a) receptor (14758 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR2C Tclin Serotonin 2c (5-HT2c) receptor (11471 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADORA1 Tclin Adenosine A1 receptor (17603 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CALCR Tclin Calcitonin receptor (2215 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC6A4 Tclin Serotonin transporter (12625 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA1A Tclin Alpha-1a adrenergic receptor (8359 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PTGS2 Tclin Cyclooxygenase-2 (13999 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HRH1 Tclin Histamine H1 receptor (7573 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA1B Tclin Alpha-1b adrenergic receptor (2912 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRM1 Tclin Mu opioid receptor (19785 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DRD3 Tclin Dopamine D3 receptor (14368 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AVPR1A Tclin Vasopressin V1a receptor (5412 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRD1 Tclin Delta opioid receptor (15096 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OPRK1 Tclin Kappa opioid receptor (16155 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC6A3 Tclin Dopamine transporter (10535 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KCNH2 Tclin HERG (29587 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HTR4 Tclin Serotonin 4 (5-HT4) receptor (2068 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ESR2 Tclin Estrogen receptor beta (9272 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYSLTR1 Tclin Cysteinyl leukotriene receptor 1 (2118 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ERBB2 Tclin Receptor protein-tyrosine kinase erbB-2 (7851 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHRM4 Tclin Muscarinic acetylcholine receptor M4 (6041 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHRM5 Tclin Muscarinic acetylcholine receptor M5 (4677 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ADRA2B Tclin Alpha-2b adrenergic receptor (4412 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Obiettivi associati (non umani)
Agtr2 Angiotensin II type 2 (AT-2) receptor (803 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mc4r Melanocortin receptor 4 (1205 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Ltc4s Leukotriene C4 synthase (1 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Sigmar1 Sigma opioid receptor (160 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Npy1r Neuropeptide Y receptor type 1 (8 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Cckar Cholecystokinin A receptor (90 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Nos2 Nitric oxide synthase, inducible (3573 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mapk1 MAP kinase ERK2 (650 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hdac6 Histone deacetylase 6 (222 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Galc Galactocerebrosidase (11 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mmp9 Matrix metalloproteinase 9 (38 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Rattus norvegicus (775804 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Meccanismi d'azione
Certificati (CoA, COO, BSE/TSE e tabella di analisi)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Proprietà chimiche e fisiche
SolubilitàSoluble in water: 14 mg/mL
Punto di fusione (°C)214-218° C
Peso molecolare425.400 g/mol
XLogP34.300
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count3
Rotatable Bond Count4
Exact Mass424.168 Da
Monoisotopic Mass424.168 Da
Topological Polar Surface Area32.800 Ų
Heavy Atom Count28
Formal Charge0
Complexity557.000
Isotope Atom Count0
Defined Atom Stereocenter Count3
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
The total count of all stereochemical bonds0
Covalently-Bonded Unit Count1
Calcolatori di soluzioni
Recensioni

Recensioni dei clienti

Application Protocols

Only from product data

  • No tested application protocols are provided for this item.

General guidance for small-molecule assay use (non-clinical)

  • Stock preparation: dissolve in anhydrous DMSO to 10–50 mM as solubility permits; vortex and sonicate briefly. Filter through 0.2 μm PTFE if particulates persist.
  • Plate handling: dispense using calibrated acoustic or positive-displacement systems; minimize DMSO in final assay (≤0.1–0.5% v/v typically).
  • Controls: include vehicle controls matched to stock solvent; run orthogonal counterscreens to detect assay interference.
  • Storage of working stocks: aliquot into inert, amber vials or sealed plates; minimize freeze–thaw by preparing single-use portions.

Note: Adjust parameters based on the confirmed structure, solubility, and stability from the CoA.

Biological Roles

Item-specific facts (from Product Data)

  • No biological function or target information is provided for this item.

Applicability to this product

  • Without a verified structure and target annotation, no specific biological roles can be ascribed. The product is designated for research use only and is supplied as part of a small-molecule/compound library.

General guidance for users

  • Prior to biological testing, obtain or confirm the structure (CoA/Spec Sheet) and perform preliminary stability and interference assessments (e.g., redox cycling, fluorescence interference, aggregation controls).
  • Document any observed activity with full contextual details (assay format, counterscreens) to distinguish genuine target engagement from assay artifacts.

Compliance note

  • No medical or clinical claims are made or implied. This product is not intended for human or veterinary use.
Buffer Applications

Not typically applicable.

  • This product is a small-molecule library compound rather than a buffering agent. No established buffer system, pKa, or buffering range is provided or implied.
  • For assay use, prepare stocks in an appropriate solvent (commonly DMSO) and dilute into your chosen biological or biochemical buffer system validated for the assay target. Ensure the final solvent percentage and pH are compatible with assay performance.
Green Alternatives

Context

  • This item is a small-molecule library compound, not a bulk solvent or reagent. “Green alternatives” considerations therefore focus on the choice of handling solvents and processes rather than substitution of the compound itself.

Greener handling strategies (general guidance)

  • Prefer aqueous-compatible assay conditions whenever feasible, minimizing DMSO to ≤0.1–0.5% v/v in final assays to reduce solvent burden.
  • When preparing intermediate stocks, consider ethanol or isopropanol as co-solvents where compound solubility and assay biology permit; these are generally more benign than DMF or NMP.
  • Use micro-scale operations (low-volume plates, sealed storage) to reduce solvent consumption and emissions; employ plate sealing films to limit evaporation.
  • Waste reduction: segregate and recycle compatible solvents; employ high-efficiency fume hood practices to limit energy use.

Illustrative solvent comparison (general; not item-specific)

  • DMSO: excellent solvency, low vapor pressure; persistence in the environment is moderate; widely accepted in HTS.
  • Ethanol/iPrOH: renewable routes available; higher volatility may complicate dosing precision; protein denaturation risk at higher percentages.
  • Acetonitrile: good solvency, lower viscosity; petrochemical origin, toxicity and waste handling require care.

Note: Selection must be guided by the confirmed structure and solubility/stability profile from the CoA. No item-specific environmental or toxicity profile is available for this product.

Pharmaceutical Uses

Not applicable to this listing.

  • No pharmacopeial status, excipient role, or manufacturing use is specified. The product is labeled Moligand™ and categorized within a small-molecule/compound library for research use only.
  • Do not use for human or veterinary applications. If formulation studies are contemplated (e.g., for preclinical research), first obtain the exact salt form, counter-ion, and stability profile from the CoA, and conduct appropriate non-clinical assessments.
Physical Properties

Item-specific facts (from Product Data)

  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Physical constants (mp, bp, density, refractive index, pKa, logP): Not specified for this item; refer to CoA/Spec Sheet.
  • Solubility: Not specified for this item; refer to CoA/Spec Sheet.

General guidance (literature/typical practice)

  • For small-molecule screening ligands, an anhydrous DMSO primary stock is commonly used due to broad solubility. Empirically determine solubility at 10–50 mM by incremental addition and sonication; filter (0.2 μm PTFE) if needed.
  • If the compound is crystalline, a sharp melting point can help confirm identity and purity; measure under dry nitrogen to avoid hydrate/solvate effects when applicable.
  • Where acid/base functionality is suspected, measure aqueous pKa by UV-metric or potentiometric titration; estimate logD7.4 by shake-flask or chromatographic methods (HPLC retention vs. standards) to inform assay buffer compatibility.
  • Hygroscopicity/solvate formation: perform TGA/DSC to detect solvent of crystallization; Karl Fischer for water content if solution stability is sensitive.
  • Light/air sensitivity screening: expose aliquots to ambient light/air and monitor by LC at 254/220 nm to define handling limits.

Note: Do not treat literature or computed values as specifications. Use supplier CoA for official release criteria and batch-specific properties.

Quality and Grades

Item-specific facts (from Product Data)

  • Grade/Purity: Moligand™.

What Moligand™ typically implies (general information; not a specification)

  • Intended for molecular recognition studies, target-based screening, and chemical biology workflows where identity and suitability for assay use are prioritized.
  • Lots are commonly qualified by structure-confirmation methods (e.g., NMR/LC–MS) and meet internal purity thresholds appropriate for screening. Exact release tests and purity thresholds are batch-specific and provided on the CoA.

Practical implications for this item

  • Identity and purity confirmation: Rely on the provided CoA/SDS for the specific batch. If you require chromatography-grade UV background limits or metal content for specialized assays, request documentation; these are Not specified for this item; refer to CoA/Spec Sheet.
  • Stabilizers/additives: Not specified for this item; refer to CoA/Spec Sheet. If stabilizers are present, consider their potential to interfere in biochemical assays (e.g., BHT, ascorbate, or counter-ions).
  • Salt form/hydrate state: Not specified for this item; refer to CoA/Spec Sheet. Salt/hydrate can affect mass, solubility, and storage.

Recommendations for QC on receipt (general practice)

  • Verify by LC–MS (single major peak at expected m/z) and by 1H NMR for gross identity; assess purity by HPLC with PDA at multiple wavelengths (220/254/280 nm) to detect UV-active impurities. For HTS, consider orthogonal checks on a subset of plates to ensure plate-transfer integrity.
Reaction and Applications

Item-specific facts (from Product Data)

  • Manufacturer application text: Not provided for this item.

Applicability to this product

  • U-62066 is provided under the Moligand™ grade in a small-molecule/compound library category, suggesting use primarily as a screening ligand or reference compound in discovery assays. Without a disclosed structure, proposing synthetic reaction roles is not appropriate for this listing.

General research applications for library ligands (non-clinical)

  • Biochemical/biophysical screening: preparation of DMSO stocks for target-binding assays (e.g., fluorescence-based, SPR, DSF). Validate concentration by UV where possible (requires known ε) or by quantitative NMR with an internal standard.
  • Cell-free assays: assess aggregation propensity (e.g., detergent-supplemented controls) and redox interference (H2O2 detection) to avoid assay artifacts common to certain chemotypes.
  • Orthogonal confirmation: pair biochemical hits with orthogonal modalities (MS-based binding, thermal shift, or competition assays) to reduce false positives.

Best practices

  • Implement PAINS/REOS cheminformatics only after the verified structure is on file; confirm plate integrity (cherry-pick and retest) and monitor stability during storage (periodic LC re-checks of working stocks).

Note: For any synthetic chemistry use, first obtain the exact structure and functional groups from the CoA; only then select appropriate transformations and conditions.

Reaction Conditions

Not applicable without a defined structure.

  • Typical reaction conditions (solvents, catalysts, temperatures, and yields) are inherently structure- and functionality-dependent. Since the functional groups of U-62066 are not disclosed here, no reliable reaction condition guidance can be offered.

General note

  • Upon obtaining the structure, consult the relevant reaction literature for that chemotype and perform condition screens (solvent, base/acid, temperature) on milligram scale, monitoring by LC–MS/HPLC.
Safety and Handling

Item-specific facts (from Product Data)

  • Storage conditions: Store at 2–8°C.
  • Shipping: Shipped on wet ice.
  • GHS signal word, hazard statements, pictograms, classification: Not specified for this item; refer to SDS.

General safety guidance (always defer to SDS)

  • Handle in a chemical fume hood using appropriate PPE: lab coat, safety glasses, and nitrile gloves. Escalate to double-gloving and splash protection if aerosol or high-concentration solutions are handled.
  • Unknown toxicity: treat as potentially harmful if swallowed, inhaled, or in contact with skin. Avoid dust/particle generation; for solutions, cap promptly to limit volatilization or oxidation.
  • Incompatibilities: until functional groups are known, avoid strong oxidizers/reducers, strong acids/bases, and reactive metals. Keep away from ignition sources if the solvent or material is flammable.
  • First aid (overview; see SDS for details):
    • Inhalation: move to fresh air; seek medical attention if symptoms persist.
    • Skin/eye contact: rinse with water for at least 15 minutes; remove contaminated clothing; seek medical attention as needed.
    • Ingestion: rinse mouth; do not induce vomiting unless instructed by medical personnel.
  • Spill response: contain with inert absorbent; collect in compatible waste. For powders, dampen to minimize dust; for solutions, ventilate area and remove ignition sources.
  • Waste disposal: dispose of as organic chemical waste per institutional and local regulations; segregate halogenated vs non-halogenated solvents.

Note: Obtain and review the batch-specific SDS from Aladdin before use.

Solvent Selection

Item-specific facts (from Product Data)

  • No solvent preferences or solubility are specified for this item; refer to CoA/Spec Sheet.

General guidance for small-molecule screening compounds

  • Primary stock solvent: DMSO (anhydrous) is the default due to broad solvency and assay compatibility up to 0.1–1% v/v in final wells. Start at 10–50 mM stocks, adjusting to observed solubility and assay tolerances.
  • Alternative solvents for preparative handling: DMF, acetonitrile, ethanol, or isopropanol can be used where compatible. For water-compatible stocks, consider co-solvent systems (e.g., DMSO/H2O or MeCN/H2O) after confirming stability.
  • Solvent selection framework:
    • If ionizable: prepare as a salt in aqueous buffers or use minimal DMSO with pH adjustment (avoid extremes unless stability supported).
    • If highly lipophilic: use DMSO or DMF; for biological assays, pre-dilute into media with carrier protein (e.g., 0.1% BSA) to mitigate adsorption; verify assay tolerance.
    • If unstable to protic media: favor aprotic, dry solvents and minimize exposure to water.
  • Practical tips
    • Filter stocks (0.2 μm PTFE) to remove particulates; avoid PVDF/nylon if adsorption is suspected.
    • Use amber vials if chromophoric; purge headspace with inert gas for oxidation-sensitive molecules.

Note: Define solvent and concentration using small-scale solubility/stability screens prior to full assay plate preparation.

Storage and Reconstitution

Item-specific facts (from Product Data)

  • Storage condition: Store at 2–8°C.
  • Shipping condition: Shipped on wet ice.
  • Appearance and form: Not specified for this item; refer to CoA/Spec Sheet.

General guidance (typical practice for small-molecule ligands)

  • As-received storage: keep container tightly closed in original packaging at 2–8°C. Protect from light if chromophoric; consider desiccation if hygroscopicity is indicated on the CoA.
  • Long-term storage: if stability allows, for solid materials, refrigerated storage is typically sufficient; for solutions, prepare single-use aliquots and store at −20°C to −80°C to minimize degradation (verify by LC over time). Avoid repeated freeze–thaw cycles.
  • Reconstitution: dissolve in anhydrous DMSO to prepare a concentrated stock (e.g., 10–50 mM) as solubility permits. If aqueous stocks are required, perform a cosolvent addition (DMSO→buffer) with vigorous mixing to prevent precipitation. Confirm clarity visually and by a quick LC/HPLC check if critical.
  • Labeling: record concentration, solvent, date, and operator; include calculated water content or residual solvent if measured.

Stability note

  • No batch-specific stability or impurity limits are provided here. All specifications are Not specified for this item; refer to CoA/Spec Sheet. Verify stability under your storage and assay conditions before large-scale use.
Structure and Identity

Item-specific facts (from Product Data)

  • Product name/SKU: U-62066 (SKU: U333272)
  • CAS: 87151-85-7
  • PubChem CID: 55652
  • InChIKey: 251181 (note: format appears non-standard; verify on CoA/SDS)
  • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.

General identity notes (literature/typical practice)

  • “U-62066” is an internal/legacy identifier used in discovery programs; without the full structure, definitive functional group assignment, stereochemistry, and ring system description cannot be provided here.
  • For structural confirmation in-house, orthogonal methods are recommended: 1H/13C NMR, HRMS (ESI/APCI as appropriate), and, if needed, IR and 2D NMR (HSQC/HMBC). Compare against the supplier CoA reference spectra.
  • If chirality is relevant, assess by chiral HPLC or optical rotation; confirm enantiopurity versus certified reference where applicable.
  • For registry cross-checking, verify that CAS and CID resolve to a single, consistent structure before use in cheminformatics or HTS campaigns.

Describing 2D structure in words

  • Not possible without a verified structural depiction. Obtain the structure file (SDF/MOL/SMILES) from the CoA/Spec Sheet or validated databases prior to computational or SAR work.
Synthetic Utility

Limited applicability without structure disclosure.

  • Because functional groups and substitution patterns are not specified for this item, no meaningful guidance on its use as a synthetic building block can be provided.

General advice if the structure is obtained (literature/typical practice)

  • Map functional handles (e.g., halides, boronates, amines, acids) to known cross-coupling or condensation manifolds (Suzuki–Miyaura, Buchwald–Hartwig, amide couplings, etc.).
  • Check chemoselectivity and protecting-group needs via small-scale scouting experiments; use LC–MS to track conversions.
  • If chiral, plan for stereocontrol or resolution strategies and analytical verification (chiral HPLC, 2D NMR).

Recommendation

  • Request the full structural specification (SMILES/SDF) and CoA before planning any synthetic transformations or derivatizations.
Target Specificity

Only from product data

  • No target, epitope, or specificity information is provided for this item. There are no antibody/biologic attributes associated with this small-molecule product.

Conclusion

  • Target specificity is Not specified for this item; refer to CoA/Spec Sheet or internal discovery records if U-62066 is used as a reference ligand.

Hai bisogno di aiuto per scegliere la qualità?

La nostra guida alla selezione delle qualità copre purezza, stato dello stabilizzatore e idoneità all'applicazione per tutte le varianti del nostro catalogo.

Visualizza la guida alle qualità Moligand™ →

Desidera che le inviamo un messaggio quando avremo sconti disponibili?

Ricordamelo più tardi

Grazie! Controlli la sua casella di posta per confermare.

Ops! Le notifiche sono disabilitate.